Heavy Metal Containing (including Salts) Patents (Class 514/184)
  • Patent number: 10689415
    Abstract: Conjugates of porphyrin, chlorophyll and bacteriochlorophyll photosensitizers with RGD-containing peptides or RGD peptidomimetics are provided that are useful for photodynamic therapy (PDT), particularly vascular-targeted PDT (VTP), of tumors and nonneoplastic vascular diseases such as age-related macular degeneration, and for diagnosis of tumors by different techniques.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: June 23, 2020
    Assignee: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
    Inventors: Avigdor Scherz, Yoram Salomon, Efrat Rubinstein, Alexander Brandis, Doron Eren, Karin Neimann
  • Patent number: 10646476
    Abstract: The present invention concerns compositions for the increase in the humoral secretion comprising imidazole peptides or extracts containing them, as well as the use of said compositions for the prevention and/or treatment of secretarial dysfunctions of the body mucosa.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: May 12, 2020
    Assignee: Metis Healthcare S.r.l.
    Inventors: Cristiano Umberto Rumio, Francesco Palladini
  • Patent number: 10548849
    Abstract: The present invention relates to dosage forms of gallium complexes suitable for oral delivery and methods of preparation thereof. Such dosage forms are useful for the treatment of diseases, including, but not limited to, cancer.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: February 4, 2020
    Assignee: Altum Pharmaceuticals Inc.
    Inventors: Rickey Roy Rhinebarger, Gina G. Stetsko
  • Patent number: 10512640
    Abstract: Methods and compositions for treating disorders of the nail and nail bed. Such compositions contain a vehicle in which all components of the composition are dissolved, suspended, dispersed, or emulsified, a non-volatile solvent, a wetting agent, and a pharmaceutically active ingredient that is soluble in the non-volatile solvent and/or a mixture of the vehicle and the non-volatile solvent, and which composition is effective in treating a disorder of the nail or nail bed.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: December 24, 2019
    Assignee: Dow Pharmaceutical Sciences, Inc.
    Inventors: Gareth Winckle, Gregory T. Fieldson
  • Patent number: 10507213
    Abstract: Gold(I)-carbene complexes having a selenium donor ligand with anti-cancer activity and a method of treating cancer. Methods of treating cancer comprising administering the complexes are also provided.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: December 17, 2019
    Assignee: King Fahd University of Petroleum and Minerals
    Inventors: Adam A. A. Sulaiman, Mohammad Altaf, Anvarhusein A. Isab
  • Patent number: 10508094
    Abstract: Methods for producing ferric maltol compositions, such as ferric trimaltol, from ferrous hydroxides, are described, as well as ferric maltol compositions produced by these methods and their uses.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: December 17, 2019
    Assignee: SHIELD TX (UK) LIMITED
    Inventors: Jonathan Joseph Powell, Nuno Jorge Rodrigues Faria
  • Patent number: 10494394
    Abstract: The invention is directed to platinum(II) complexes comprising dithiocarbamates and methods for treating cancer using these complexes.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: December 3, 2019
    Assignee: King Fahd University of Petroleum and Minerals
    Inventors: Anvarhusein A. Isab, Muhammad Altaf, Muhammad Ali Ehsan, Khalid Omer
  • Patent number: 10434194
    Abstract: A PSMA targeted nanobubble includes a membrane that defines at least one internal void, which includes at least one gas, and at least one PSMA ligand coupled or conjugated to the membrane. The membrane includes at least one lipid and at least one nonionic triblock copolymer that is effective to control the size of the nanobubble without compromising in vitro and in vivo echogenicity of the nanobubble.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: October 8, 2019
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: James R. Basilion, Agata Exner, Xinning Wang, Christopher Hernandez
  • Patent number: 10406238
    Abstract: The invention described herein pertains to ligand-ionophore conjugates, that may also comprise a linked therapeutic agent or imaging agent, and pharmaceutical compositions containing the conjugates. Also described are methods of using the conjugates for increasing the endosomal accumulation and escape of a therapeutic agent, or an imaging agent.
    Type: Grant
    Filed: May 11, 2016
    Date of Patent: September 10, 2019
    Assignee: Purdue Research Foundation
    Inventors: Philip Stewart Low, Venkatesh Chelvam
  • Patent number: 10363313
    Abstract: Compounds that are PSMA ligands, pharmaceutical compositions comprising these compounds, methods for treating and detecting cancers in a subject, methods for identifying cancer cells in a sample are described herein.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: July 30, 2019
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: James Basilion, Xinning Wang, Clemens Burda
  • Patent number: 10258662
    Abstract: Provided is a method for preventing or treating hepatitis C by administrating a composition including, as an active ingredient, a Vitidis Vinferae Radix extract or a fraction thereof and, more specifically, to a Vitidis Vinferae Radix extract which is extracted with water and alcohol or a mixed solvent thereof, or a fraction thereof, which have remarkably low hepatotoxicity and exhibit an excellent effect of selectively inhibiting genome replication of a hepatitis C virus, and thus can be useful for preventing or treating hepatitis C.
    Type: Grant
    Filed: April 29, 2014
    Date of Patent: April 16, 2019
    Assignees: DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION
    Inventors: Choongho Lee, Tae Hwe Heo, Kee Dong Yoon
  • Patent number: 10179120
    Abstract: The present invention relates to a dosage regimen of ST10 (ferric trimaltol) for the treatment of patients suffering from iron deficiency with or without anaemia. Specifically the invention relates to the treatment of patients with 30 mg ST10 twice daily.
    Type: Grant
    Filed: January 6, 2015
    Date of Patent: January 15, 2019
    Assignee: Iron Therapeutics Holdings AG
    Inventors: Christian Schweiger, Carl Andrew Sterritt, Julian David Howell
  • Patent number: 10132145
    Abstract: Produced water, for example from a steam assisted gravity drainage (SAGD) or cyclic steam stimulation (CSS) heavy oil recovery operation, is treated to recover water that is re-used to create steam. The produced water is treated in one or more thermal treatment devices such as an evaporator and a crystallizer. The thermal treatment produces a slurry comprising dispersed or dissolved salts and organic compounds. A water-miscible solvent for one or more of the organic compounds, for example methanol, is added to the slurry. The solids precipitate and are separated from the slurry. The solvent may be recovered for re-use in treating more slurry.
    Type: Grant
    Filed: August 22, 2013
    Date of Patent: November 20, 2018
    Assignee: BL Technologies, Inc.
    Inventors: Jiyang Xia, Wenqing Peng, Hai Yang, Chunjie Liu, Chang Wei, Wei Cai, Yiwen Sun
  • Patent number: 10124085
    Abstract: The present invention relates to hygienic products such as sanitary pads and tampons, patient/adult diapers and baby diapers which are made antimicrobial. In the present invention, a mixture of glucopon, chlorhexidine gluconate and triclosan is obtained from the boron compounds called sodium borate, zinc borate, sodium perborate tetrahydrate, borax pentahydrate and disodium octaborate tetrahydrate; and this mixture provides antifungal, anticandidal, antibacterial and antiviral properties to the woven or non-woven textile products and hygienic products. Additionally, the said hygienic products are made hydrophilic by means of the invention.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: November 13, 2018
    Assignee: YEDITEPE UNIVERSITESI
    Inventors: Fikrettin Sahin, Zeynep Ustaoglu, Selami Demirci, Okan Demir, Ayla Burcin Asutay
  • Patent number: 10111936
    Abstract: Compositions of the invention include glycoproteins, such as transferrin, and metal-based coordination complexes, which are preferably chemotherapeutic compounds and more preferably tunable photodynamic compounds. The compositions are useful as in vivo diagnostic agents, and as therapeutic agents for treating or preventing diseases including those that involve hyperproliferating cells in their etiology, such as cancer. Compositions of the invention are further capable of destroying microbial cells, such as bacteria, fungi, and protozoa, and destroying viruses. Treatment methods of the invention can treat conditions throughout the body, including conditions located across the blood-brain barrier, the retina-blood barrier and the blood-cerebrospinal fluid barrier.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: October 30, 2018
    Assignee: Theralase Technologies, Inc.
    Inventor: Arkady Mandel
  • Patent number: 10053432
    Abstract: The present invention relates to compounds of the formula I and the N-oxides and the salts thereof for combating phytopathogenic fungi, and to the use and methods for combating phytopathogenic fungi and to seeds coated with at least one such compound. The invention also relates to processes for preparing these compounds, intermediates, processes for preparing such intermediates, and to compositions comprising at least one compound I.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: August 21, 2018
    Assignee: BASF SE
    Inventors: Wassilios Grammenos, Nadege Boudet, Bernd Müller, Maria Angelica Quintero Palomar, Ana Escribano Cuesta, Erica May Cambeis, Jan Klaas Lohmann, Thomas Grote, Manuel Kretschmer, Ian Robert Craig
  • Patent number: 9898578
    Abstract: Systems and methods for displaying gene- and/or protein-related data with respect to chromosome maps at locations identifying relevant positioning of the genes with which the gene- and/or protein related data are associated. Multiple experiments may be plotted onto the display adjacent one or more chromosome maps. Automatic extraction of genomic location, based on accession numbers or other unique identifiers and cross connection with expression data is provided. Statistical assessments of correlations between expression and genome localization may be performed. Zooming capabilities, thumbnail/fullview toggling, browsability and linked data may be included as features of the visualization systems described.
    Type: Grant
    Filed: April 3, 2004
    Date of Patent: February 20, 2018
    Assignee: Agilent Technologies, Inc.
    Inventors: Zohar Yakhini, Robert Kincaid, Amir Ben-Dor, Leslie A. Leonard, Nicholas M. Sampas
  • Patent number: 9889199
    Abstract: Compounds that are PSMA ligands, pharmaceutical compositions comprising these compounds, methods for treating and detecting cancers in a subject, methods for identifying cancer cells in a sample are described herein. Prostate-specific membrane antigen (PSMA) is a 120 kDa protein expressed in prostate tissues and was originally identified by reactivity with a monoclonal antibody designated 7EII-C5 (Horoszewicz et al., 1987, Anticancer Res. 7:927-935; U.S. Pat. No. 5,162,504). PSMA is characterized as a type II transmembrane protein sharing sequence identity with the transferrin receptor (Israeli et al., 1994, Cancer Res. 54:1807-1811).
    Type: Grant
    Filed: February 18, 2014
    Date of Patent: February 13, 2018
    Assignee: Case Western Reserve University
    Inventors: James Basilion, Xinning Wang, Clemens Burda
  • Patent number: 9878998
    Abstract: Provided are methods and compositions for use in therapy, and in particular for treating cancer, preferably drug-resistant cancer, and/or radiation resistant cancer. The compounds may be used for reducing tumor size in a mammalian subject and for inducing apoptosis in a tumor cell. The methods are effective on tumor cells that are resistant to drugs such as temozolomide, doxorubicin, and geldanamycin, as well as non-resistant tumor cells. Further provided are barbiturate and thiobarbiturates diene compounds for use in treating cancer, and uses, methods and compositions relating to these compounds.
    Type: Grant
    Filed: August 15, 2012
    Date of Patent: January 30, 2018
    Assignee: NUHOPE LLC
    Inventors: James R. Connor, Sang Yong Lee
  • Patent number: 9868750
    Abstract: The present invention relates to a 4,5-diarylimidazole derivative of formulae (I), (II) or (III): or a pharmaceutically acceptable salt thereof, wherein the 4,5-diarylimidazole derivative has a hydroxamic acid residue at a first aryl ring and a residue R1 at a second aryl ring; and wherein R1 is hydrogen, a halogen atom or an unsubstituted or substituted alkoxy group; R2 is independently selected from an unsubstituted or substituted alkyl, alkoxy or alkene group; M is a metal atom; L is a halogen atom, an unsubstituted or substituted phosphane, sulfane, arene or alkene group or a 4,5-diarylimidazole-derivative of formula (I); and n is an integer of from 1 to 5.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: January 16, 2018
    Assignees: CHARITÉ—UNIVERSITÄTSMEDIZIN BERLIN, UNIVERSITÄT BAYREUTH
    Inventors: Michael Höpfner, Bernhard Biersack, Rainer Schobert, Katharina Mahal
  • Patent number: 9870930
    Abstract: Methods for producing a substrate for semiconductor element mounts are provided. A base substrate can be prepared having on a first metal layer, a second metal layer through which a metal layer for instrumentation is hardly diffusible. A patterned resist mask layer on the second metal layer can be formed. A surface of the second metal layer under reprocessing treatment can form a reprocessed surface which can be provided with an organic film that controls adhesion between the metal layer for instrumentation and the reprocessed surface by a liquid agent containing a component that shows the nature of amphoteric surfactant. The metal layer for instrumentation can be formed on the reprocessed surface via the organic film. A semiconductor element mount portion and an electrode terminal portion can be electroformed on the metal layer for instrumentation. The resist mask from the second metal layer of the base substrate may be removed.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: January 16, 2018
    Assignee: SH MATERIALS CO., LTD.
    Inventors: Kaoru Hishiki, Shunichi Kidoguchi, Hiroki Nakayama
  • Patent number: 9861591
    Abstract: Provided is a nitric oxide-releasing wound treatment film containing S-nitroglutathione, which is a nitric oxide donor to be spontaneously formed in the human body, has mechanical characteristics enabled to be applied to the human body, slowly releases nitric oxide and inhibits a pathogen, which is the main cause of wound infection, and can quickly heal a wound, and thus the film can be useful for treating a wound.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: January 9, 2018
    Assignee: PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION
    Inventor: Jin Wook Yoo
  • Patent number: 9861568
    Abstract: The present disclosure provides a composition for improving skin condition comprising chlorophyll a or pheophorbide a as an active ingredient. According to the present disclosure, chlorophyll a or pheophorbide a exhibits an effect of improving skin wrinkles and inflammatory reaction due to ultraviolet lights. The composition of the present disclosure is characterized by oral administration and can be provided as a cosmetic composition, a pharmaceutical composition or a food composition.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: January 9, 2018
    Assignee: GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Yong Chul Kim, Jung Hyun Han, Hyun You, Min-Jeong Kim
  • Patent number: 9856280
    Abstract: The invention relates to a method for producing aqueous preparations of complexes of platinum group metals (PGM) Pt, Pd, Rh and Ir having the general formula [MA/MB/MC(L)a(H2O)b(O2—)c(OH?)d](OH—)e(H+)f, wherein MA=PtII or PdII, MB=PtIV, MC=Rh or Ir, L is a neutral monodentate or bidentate donor ligand, and a is an integer between 1 and 4 (or 2) and/or between 1 and 6 (or 3), b is an integer between 0 and 3 (or 5), c is an integer between 0 and 3 (or 4), d is an integer between 0 and 3 (or 5), e is an integer between 0 and 2 (or 3 or 4) and f is an integer between 0 and 4 (or 5). In the method according to the invention, the hydroxo complexes H2Pd(OH)4 (in the case of MA=PdII), H2Pt(OH)6 (in the case of MA=PtII and MB=PtIV) or H3MC(OH)6 (for MC=RhIIIIrIII) are converted in the presence of the donor ligands, wherein at least one hydroxo group of the hydro complex is exchanged. Preferably, the reaction occurs at temperatures in the range of 40 to 110° C.
    Type: Grant
    Filed: December 11, 2013
    Date of Patent: January 2, 2018
    Assignee: Umicore AG & Co., KG
    Inventors: Eileen Woerner, Ralf Karch, Andreas Rivas-Nass, Angelino Doppiu
  • Patent number: 9737565
    Abstract: Compositions of the invention include glycoproteins, such as transferrin, and metal-based coordination complexes, which are preferably chemotherapeutic compounds and more preferably tunable photodynamic compounds. The compositions are useful as in vivo diagnostic agents, and as therapeutic agents for treating or preventing diseases including those that involve hyperproliferating cells in their etiology, such as cancer. Compositions of the invention are further capable of destroying microbial cells, such as bacteria, fungi, and protozoa, and destroying viruses.
    Type: Grant
    Filed: January 19, 2016
    Date of Patent: August 22, 2017
    Assignee: THERALASE TECHNOLOGIES, INC.
    Inventor: Arkady Mandel
  • Patent number: 9725434
    Abstract: The present invention is directed to hydroxy compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Grant
    Filed: April 21, 2014
    Date of Patent: August 8, 2017
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Scott D. Kuduk, Nigel L. Liverton, Jason W. Skudlarek
  • Patent number: 9695123
    Abstract: Compounds of formula (I) wherein the other substituents HetAr, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined in claim 1, and their use in compositions and methods for the control and/or prevention of microbial infection, particularly fungal infection, in plants and to processes for the preparation of these compounds.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: July 4, 2017
    Assignee: Syngenta Participations AG
    Inventors: Stephane Andre Marie Jeanmart, Ramya Rajan, Damien Bonvalot, Francesca Perrucio
  • Patent number: 9655363
    Abstract: Compounds of formula (I) wherein the other substituents MBG, HetAr, R1, R2, R and R4 are as defined in claim 1, and their use in compositions and methods for the control and/or prevention of microbial infection, particularly fungal infection, in plants and to processes for the preparation of these compounds.
    Type: Grant
    Filed: January 28, 2014
    Date of Patent: May 23, 2017
    Assignee: Syngenta Participations AG
    Inventors: Stephane Andre Marie Jeanmart, Damien Bonvalot
  • Patent number: 9605012
    Abstract: The described invention provides organometallic complexes capable of spin transfer, comprising at least three different metals and the use of pharmaceutical compositions comprising such complexes in detoxification of reactive oxygen species in inflammatory conditions.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: March 28, 2017
    Assignee: Garnett McKeen Laboratory, Inc.
    Inventor: Merrill Garnett
  • Patent number: 9561237
    Abstract: Platinum(II) complexes having mixed ligands as anticancer agents. The central platinum atom is coordinated by two phosphine ligands and two heterocyclic thione ligands. Each heterocyclic thione ligand has a five-, six- or seven-membered heterocyclic ring with two nitrogen atoms at positions 1 and 3 of the ring and a thiocarbonyl group at position 2. Pharmaceutical compositions incorporated the platinum(II) complexes, methods of synthesizing the complexes and methods of treating cancers with the complexes or pharmaceutical compositions thereof are also described.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: February 7, 2017
    Assignee: King Fahd University of Petroleum and Minerals
    Inventors: Anvar Husain Abdul Kadir Isab, Muhammad Altaf
  • Patent number: 9534007
    Abstract: A composition and method for treating excess cyanide and hydrogen sulfide comprising administering a cobinamide. Further a method for determining extent of binding by an agent to an extracellular matrix.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: January 3, 2017
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE AIR FORCE
    Inventors: Gerry Boss, Adriano Chan, Matthew Brenner, Sari Brenner-Mahon, Vikhyat S. Bebarta, Jingjing Jiang, Karen Christman, Jean Wang Wassenaar
  • Patent number: 9529976
    Abstract: Systems, methods, and devices for detecting infections in a clinical sample are provided. Small-volume clinical samples obtained at a point-of-service (POS) location and may be tested at the POS location for multiple markers for multiple diseases, including upper and lower respiratory diseases. Samples may be tested for cytokines, or for inflammation indicators. Dilution of samples, or levels of detection, may be determined by the condition or past history of a subject. Test results may be obtained within a short amount of time after sample placement in a testing device, or within a short amount of time after being obtained from the subject. A prescription for treatment of a detected disorder may be provided, and may be filled, at the POS location. A bill may be automatically generated for the testing, or for the prescription, may be automatically sent to an insurance provider, and payment may be automatically obtained.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: December 27, 2016
    Assignee: Theranos, Inc.
    Inventors: Clarissa Lui, Elizabeth A. Holmes
  • Patent number: 9492494
    Abstract: An object of the present invention is to provide an oral composition useful for promoting collagen synthesis and the like. The present invention can provide an oral composition containing collagen or gelatin or a degradation product thereof, and hydroxyproline or a salt thereof. The weight ratio of alanine and hydroxyproline contained in the amino acids obtained by hydrolyzing the oral composition is preferably 1:1.5-150.
    Type: Grant
    Filed: May 30, 2008
    Date of Patent: November 15, 2016
    Assignee: Kyowa Hakko Bio Co., Ltd.
    Inventors: Ayako Kamimura, Yasushi Sakai, Takeshi Ikeda
  • Patent number: 9439910
    Abstract: The invention relates to iron(III) complex compounds and pharmaceutical compositions comprising them for the use as medicaments, in particular for the treatment and/or prophylaxis of iron deficiency symptoms and iron deficiency anemias.
    Type: Grant
    Filed: April 4, 2013
    Date of Patent: September 13, 2016
    Assignee: VIFOR (INTERNATIONAL) AG
    Inventors: Thomas Bark, Wilm Buhr, Susanna Burckhardt, Michael Burgert, Camillo Canclini, Franz Dürrenberger, Felix Funk, Peter Otto Geisser, Aris Kalogerakis, Simona Mayer, Erik Philipp, Stefan Reim, Diana Sieber, Jörg Schmitt, Katrin Schwarz
  • Patent number: 9345725
    Abstract: The present invention relates to pharmaceutical formulations containing a pharmaceutically acceptable gallium salt (such as gallium nitrate), a delivery agent, and optionally, one or more chemotherapeutic agents and/or adjunctive chemotherapeutic agents.
    Type: Grant
    Filed: December 29, 2005
    Date of Patent: May 24, 2016
    Assignee: EMISPHERE TECHNOLOGIES, INC.
    Inventors: Lewis Bender, Bavani Shankar, Catherina O'Shaughnessy
  • Patent number: 9289417
    Abstract: Methods for regulating the formation of a sulfilimine crosslink in a subject by administering a sulfilimine crosslink modulator are disclosed The sulfilimine modulator may inhibit or create a sulfilimine crosslink and maybe useful for treating a disease, such as cancer The sulfilimine crosslink may be between two or more peptides.
    Type: Grant
    Filed: June 11, 2010
    Date of Patent: March 22, 2016
    Assignee: VANDERBILT UNIVERSITY
    Inventors: Billy G. Hudson, Roberto Vanacore, Gautam Bhave, Vadim Pedchenko
  • Patent number: 9200086
    Abstract: Nanosilver coated bacterial cellulose nanofiber and a method of producing the nanosilver coated bacterial cellulose nanofiber. The nanosilver coated bacterial cellulose nanofiber is produced by preparing a suspension of bacterial cellulose fibers, oxidizing bacterial cellulose fibers; adding the thio-group to the polymer backbone; reacting the resulting product with silver proteinate and enhancing the nanosilver particle size. The nanosilver coated bacterial cellulose nanofibers exhibit antimicrobial properties.
    Type: Grant
    Filed: February 4, 2013
    Date of Patent: December 1, 2015
    Assignee: AXCELON BIOPOLYMERS CORPORATION
    Inventors: Wankei Wan, Ganesh Guhados
  • Patent number: 9096628
    Abstract: Substituted metalloporphyrin compounds are described, along with pharmaceutical compositions containing the same, and methods of use thereof in protecting cells from oxidant-induced toxicity and pathological conditions such as inflammatory lung disease, neurodegenerative conditions, radiation injury, cancer, diabetes, cardiac conditions and sickle cell disease. Mn(III) porphyrins bearing oxygen atoms within side chains are particularly described.
    Type: Grant
    Filed: November 22, 2013
    Date of Patent: August 4, 2015
    Assignee: Duke University
    Inventors: Ines Batinic-Haberle, Irwin Fridovich, Ivan Spasojevic
  • Patent number: 9089578
    Abstract: Methods and compositions for treating neuroendocrine tumors are disclosed.
    Type: Grant
    Filed: April 25, 2013
    Date of Patent: July 28, 2015
    Assignee: Intezyne Technologies, Inc.
    Inventors: Hooshmand Sheshbaradaran, William McCulloch
  • Patent number: 9040513
    Abstract: Described is a process for preparing platinum-carbene complexes.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: May 26, 2015
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVRSITE DE STRASBOURG
    Inventors: Stéphane Bellemin-Laponnaz, Gilles Guichard, Edith Chardon
  • Publication number: 20150139901
    Abstract: The present invention concerns radioactive rhodium complexes, their preparation methods, and their use for the radiolabelling of biomolecules, especially monoclonal antibodies.
    Type: Application
    Filed: May 14, 2013
    Publication date: May 21, 2015
    Applicants: Institut National de la Sante et de la Recherche (INSERM), Chu Nantes, Universite de Nantes, Centre National de la Recherche Scientifique (C.N.R.S.), Universite d' Angers
    Inventors: Alain Faivre-Chauvet, Holisoa Rajaerison, Jean-Francois Gestin
  • Publication number: 20150132406
    Abstract: A method of selecting or determining a candidate compound suitable for use as a phosphate binder is disclosed. The candidate compound includes ferric compounds, ferric compound complexes, and their derivatives, salts, analogs, and metabolites. The effectiveness of the candidate compound as a phosphate binder is evaluated by a method, comprising measuring and correlating reduction of phosphate concentration in solution and reduction of phosphate absorption in cells.
    Type: Application
    Filed: January 12, 2015
    Publication date: May 14, 2015
    Inventor: Keith Chan
  • Patent number: 9023838
    Abstract: The present invention relates to crystalline Form I rosuvastatin zinc (2:1) salt, method of preparation thereof and use thereof as pharmaceutically active ingredient for the treatment of diseases related to lipid metabolism including hyperlipoproteinemia, hypercholesteremia, dyslipidemia and atherosclerosis.
    Type: Grant
    Filed: July 24, 2009
    Date of Patent: May 5, 2015
    Assignee: Egis Gyogyszergyar Nyilvanosan Muekoedoe
    Inventors: Ferenc Bartha, Gyoergyi Kovanyine Lax, Balazs Volk, Jozsef Barkoczy, Gyoergy Morovjan, Gyoergy Krasznai, Kalman Nagy, Gyula Simig, Gyoergy Ruzsics, Gyoergy Clementis, Imre Kapui, Peter Slegel, Adrienn Keszthelyi, Zsuzsanna Szent-Kirallyi, Valeria Hoffmanne Fekete, Janos Imre
  • Patent number: 9023402
    Abstract: Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and/or known anti-inflammatory drugs, such as aspirin.
    Type: Grant
    Filed: April 1, 2011
    Date of Patent: May 5, 2015
    Assignee: ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda.
    Inventors: Werner E. Haas, Carlos C. Romao, Beatriz Royo, Ana Cristina Fernandes, Isabel Goncalves
  • Publication number: 20150119374
    Abstract: The invention relates to iron(III) complex compounds and pharmaceutical compositions comprising them for the use as medicaments, in particular for the treatment and/or prophylaxis of iron deficiency symptoms and iron deficiency anemias.
    Type: Application
    Filed: April 4, 2013
    Publication date: April 30, 2015
    Inventors: Thomas Bark, Wilm Buhr, Susanna Burckhardt, Michael Burgert, Camillo Canclini, Franz Dürrenberger, Felix Funk, Peter Otto Geisser, Aris Kalogerakis, Simona Mayer, Erik Philipp, Stefan Reim, Diana Sieber, Jörg Schmitt, Katrin Schwarz
  • Patent number: 9018199
    Abstract: The present invention relates to organometallic compounds useful in the treatment of metastasis. The organometallic compounds comprise a ligand that is covalently bound to a bioactive compound, which is an inhibitor of a resistance pathway or a derivative thereof. Preferably, the organometallic compounds are half-sandwich (“piano-stool”) compounds. The compounds of the present invention offer a high variability with respect to the bioactive compound and to the nature of the ligand bound to a central transition metal.
    Type: Grant
    Filed: May 9, 2007
    Date of Patent: April 28, 2015
    Assignee: Ecole Polytechnique Federale de Lausanne (EPFL)
    Inventors: Paul Joseph Dyson, Wee Han Ang
  • Patent number: 9011933
    Abstract: A novel method for treating skin and mucosal membrane ailments caused by human papilloma viruses, which utilizes tellurium-containing compounds, is disclosed. Also disclosed are pharmaceutical compositions containing tellurium-containing compounds for treating such ailments.
    Type: Grant
    Filed: January 23, 2005
    Date of Patent: April 21, 2015
    Assignee: Biomas Ltd.
    Inventors: Benjamin Sredni, Michael Albeck
  • Patent number: 8987451
    Abstract: A single-step method of making tetradentate platinum complexes is disclosed. The method advantageously allows the formation of a platinum complex in a single step, even with sterically hindered ligands, without the use of highly reactive intermediates. The compounds made by the disclosed method are useful in OLED applications.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: March 24, 2015
    Assignee: Universal Display Corporation
    Inventors: Jui-Yi Tsai, Gregg Kottas, Walter Yeager
  • Publication number: 20150080354
    Abstract: Medicaments and methods for treating cancer are disclosed.
    Type: Application
    Filed: May 17, 2012
    Publication date: March 19, 2015
    Applicant: NikiI Pharma Inc.
    Inventor: Hooshmand Sheshbaradaran
  • Patent number: 8980875
    Abstract: The invention relates to the platinum N-heterocycle derivatives of general formula (I) in which—R1 and/or R2 are, independently of one another, an aryl or aralkyl group, each optionally substituted, a linear or branched C1-C6 alkyl group, a monocyclic C3-C7 cycloalkyl group or a linear or branched C2-C6 alkenyl group, or else R? is a hydrogen atom and R is a group selected from the following groups: cycloalkyl or heterocycloalkyl, which is monocyclic or bicyclic and has from 3 to 8 carbon atoms, or benzyl, which is optionally substituted, or else R and R? form, together with NH, a C3-C8 monocyclic or bicyclic heterocycloalkyl, V is a nitrogen atom or a C—R4 radical, R3 and/or R4 are hydrogen or a phenyl group or R3 and R4 may also together form a C3-C6 alkylene radical or a C3-C6 heteroalkylene radical with one or more nitrogenous heteroatoms, it being possible for the carbon atoms of the heteroalkylene radical to be modified in the form of a carbonyl radical, and X is iodine, bromine, chlorine or a nitra
    Type: Grant
    Filed: June 21, 2013
    Date of Patent: March 17, 2015
    Assignee: Centre National de la Recherche Scientifique
    Inventors: Patrick Mailliet, Angela Marinetti, Myriem Skander